SaniHaiderKizilbashMDMPH

Oncology • Rochester, MN

Neuro-Oncology

Associate Professor, Division of Medical Oncology, Mayo Clinic

Join to view full profile

Dr. Kizilbash is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kizilbash's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2011 - 2014
Emory UniversityMPH, Health Outcomes, 2008 - 2011
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2005 - 2008
Aga Khan Medical CollegeClass of 2003

Certifications & Licensure

MN State Medical License 2011 - 2025
FL State Medical License 2016 - 2019
MI State Medical License 2005 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Start of enrollment: 2011 Oct 01
Completed
Phase 1, Phase 2
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma Start of enrollment: 2019 May 01
Active, not recruiting
Phase 1
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases Start of enrollment: 2019 Dec 20
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

399 citations
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Jann N. Sarkaria, Leland S. Hu, Ian F. Parney, Deanna H. Pafundi, Debra H. Brinkmann
Neuro-Oncology. 2018-01-22
63 citations
Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system
Karen E. Parrish, Ling Cen, James W. Murray, David Calligaris, Sani H. Kizilbash
Molecular Cancer Therapeutics. 2015-12-01
25 citations
Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma
Nadia N. Laack, Deanna H. Pafundi, S. Keith Anderson, Timothy J. Kaufmann, Val J. Lowe
International Journal of Radiation Oncology, Biology, Physics. 2020-11-01

Lectures

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astro...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Beating Back a Brain Tumor Amid LossJune 17th, 2019

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
Society of Neuroncology
Member

Other Languages

Urdu

External Links

Mayo Clinichttp://www.mayoclinic.org/biographies/kizilbash-sani-h-mbbs-m-p-h/bio-20116924